CoLucid Pharmaceuticals, Inc. CLCD was a big mover last session, as the company saw its shares rise roughly 10% on the day. The move came on solid volume too with far more shares changing hands than ...

Towards the end of August, we published this piece detailing two major potential upside catalysts to keep an eye on early September. One of the companies we profiled was CoLucid Pharmaceuticals Inc ...

CoLucid Pharmaceuticals, Inc. CLCD was a big mover last session, as its shares rose over 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.

The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research ...

Find the latest (CLCD) stock quote, history, news and other vital information to help you with your stock trading and investing.

CAMBRIDGE, Mass., Dec. 8, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, ...

CLCD, a provider of children’s literature database products for educators and librarians in the United States, is releasing CLCD Enterprise Version 7.0, a milestone achievement that aims to transform ...

On Wednesday, shares of biopharmaceutical company CoLucid Pharmaceuticals CLCD are skyrocketing, up around 32% in midday trading after Eli Lilly and Co. announced it is buying the company for a ...

A brief overview of the NASDAQ:CLCD financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance ...